The patients who are homozygous for the p.Asp444His pathogenic variant are expected to have serum biotinidase enzyme activity consistent with partial BTD deficiency, and thus may not require biotin therapy and should only be monitored or—if treated—low doses of biotin are recommended. The gene discussed is BTD; the disease is biotinidase deficiency.